Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, V. Vendrely et al.|The Lancet Oncology|2021Cited by 1.3k
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialThierry Conroy, Christophe Borg, Florence Castan et al.|Annals of Oncology|2024Cited by 187
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.Thierry Conroy, Christophe Borg, Najib Lamfichekh et al.|Journal of Clinical Oncology|2020Cited by 177